8-K - Zymeworks Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Zymeworks Inc. appointed Kristin Stafford as Executive Vice President and Chief Financial Officer effective April 1, 2026, succeeding Kenneth Galbraith as interim CFO while he continues as CEO.

Key Takeaways

1Kristin Stafford, age 44, appointed Executive Vice President, Chief Financial Officer effective April 1, 2026, assuming principal financial and accounting officer roles.

2Prior experience: Senior Vice President, Chief Accounting Officer at Royalty Pharma plc since December 2018; VP Finance at Royalty Pharma and CFO of BioPharma Credit plc (2016-2018).

3Annual base salary $520,000; signing bonus $52,000; options for 178,000 shares; RSUs totaling 169,000.

4Termination without cause: 12 months base salary/notice (up to 18 months after 4 years); post-Change of Control: 18 months severance plus full equity vesting.

5Kenneth Galbraith ceased interim CFO role but remains Chair, CEO, and President with unchanged compensation.

Current Report Details

Event Type

Management Change

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment o

Management Change

$520.0K$52.0K

9.01

Financial Statements and Exhibits. (d) Exhibits Exhibit No.: 10.1 | Description: Employment Agreement between Zymeworks Biopharmaceuticals Inc. and Kristin Staf

Exhibits Only

Source Document

Executive & Director Changes

Kristin Stafford

Executive Vice President, Chief Financial Officer

Appointment

Effective: 2026-04-01

Kenneth Galbraith

Interim Chief Financial Officer, principal financial officer and principal accounting officer

Cessation

Effective: 2026-04-01

Appointment of permanent CFO

Exhibits (3)

10.1

EX-10.1

8-K

99.1

EX-99.1